ELAC2 Antikörper (AA 88-190) (Cy3)
Kurzübersicht für ELAC2 Antikörper (AA 88-190) (Cy3) (ABIN706274)
Target
Alle ELAC2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 88-190
-
Kreuzreaktivität
- Human
-
Homologie
- Mouse,Rat,Dog,Rabbit
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human ELAC2
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- ELAC2 (ElaC Homolog 2 (ELAC2))
-
Andere Bezeichnung
- ELAC2
-
Hintergrund
-
Synonyms: elaC homolog 2, ElaC homolog protein 2, ELC2, Heredity prostate cancer protein 2, HPC2, putative prostate cancer susceptibility protein HPC2/ELAC2, Ribonuclease Z2, RNase Z2, tRNA 3 endonuclease 2, tRNase Z long form, tRNase Z2, Zinc phosphodiesterase ELAC protein 2.
Background: ELAC2 is a zinc phosphodiesterase which displays some tRNA 3' processing endonuclease activity. It is thought to be involved in tRNA maturation, acting by removing a 3' trailer from precursor tRNA. ELAC2 also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. A number of allelic variants have been investigated in hereditary prostate cancer.
-
Gen-ID
- 60528
Target
-